#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3216	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2510	380.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1623	1623	C	443	C,T,A,G	357,1,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3216	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2510	380.0	0	HET	.	.	.	A37T	.	37	37	A	476	476	A	514	A,T	350,95	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4674	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3937	355.3	0	.	n	.	0	T695C	SNP	695	695	T	1181	1181	C	335	C,T	281,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4674	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3937	355.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1823	1823	A	420	A	369	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4674	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3937	355.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2457	2457	C	439	C,T	370,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4674	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3937	355.3	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3083	3083	T	349	T	278	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4674	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3937	355.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2531	2531	A	470	A	390	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	480	folP	852	852	100.0	folP.l6.c4.ctg.1	1944	73.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1239	1241	AGC	118;118;119	A;G;C	103;100;99	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1026	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3842	80.1	1	SNP	p	S91F	0	.	.	271	273	TCC	797	799	TCC	92;93;93	T;C;C	76;80;82	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1026	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3842	80.1	1	SNP	p	D95G	0	.	.	283	285	GAC	809	811	GAC	93;93;94	G;A;C	79;80;78	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1026	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3842	80.1	1	SNP	p	D95N	0	.	.	283	285	GAC	809	811	GAC	93;93;94	G;A;C	79;80;78	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	456	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1695	80.8	0	.	p	.	0	A39T	NONSYN	115	117	GCC	636	638	ACC	125;125;125	A;C;C	101;104;104	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	456	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1695	80.8	0	.	p	.	0	R44H	NONSYN	130	132	CGC	651	653	CAC	130;131;131	C;A;C	106;106;109	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	456	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1695	80.8	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	834	836	CAC	134;134;134	C;A;C	115;115;117	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	456	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1695	80.8	1	SNP	p	G45D	0	.	.	133	135	GGC	654	656	GGC	131;131;131	G;G;C	109;106;107	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	332	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1460	68.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1242	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3297	112.6	1	SNP	p	D86N	0	.	.	256	258	GAC	654	656	GAC	148;147;147	G;A;C,T	126;121;124,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1242	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3297	112.6	1	SNP	p	S87R	0	.	.	259	261	AGT	657	659	AGT	147;148;148	A,C;G;T	120,1;126;128	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1242	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3297	112.6	1	SNP	p	S87I	0	.	.	259	261	AGT	657	659	AGT	147;148;148	A,C;G;T	120,1;126;128	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1242	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3297	112.6	1	SNP	p	S87W	0	.	.	259	261	AGT	657	659	AGT	147;148;148	A,C;G;T	120,1;126;128	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1242	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3297	112.6	1	SNP	p	S88P	0	.	.	262	264	TCC	660	662	TCC	148;147;147	T;C,A;C	125;127,1;127	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	968	parE	1986	1986	100.0	parE.l6.c17.ctg.1	3064	94.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1771	1773	GGC	130;130;132	G;G,A;C	107;105,1;105	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	832	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2649	93.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1344	1346	GCA	126;124;126	G;C,T;A	100;98,1;99	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	832	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2649	93.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1347	1349	ATC	125;125;123	A;T;C,T	101;100;102,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	832	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2649	93.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1359	1361	GTG	127;127;130	G;T;G	104;101;102	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	832	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2649	93.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1359	1361	GTG	127;127;130	G;T;G	104;101;102	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	832	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2649	93.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1863	1865	ACC	115;115;115	A;C;C,A	97;96;96,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	832	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2649	93.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1917	1919	GCG	108;106;106	G;C;G	90;86;82	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	832	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2649	93.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1917	1919	GCG	108;106;106	G;C;G	90;86;82	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	832	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2649	93.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2040	2042	GGC	101;101;101	G,C;G;C	84,1;87;90	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	832	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2649	93.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2049	2051	GGC	103;102;101	G,C;G,A;C	90,2;86,1;89	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	832	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2649	93.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2067	2069	CCG	99;99;99	C;C;G	79;85;82	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1222	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3587	102.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	618	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2197	83.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	777	777	C	99	C,T	86,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	76	porB1a	984	331	90.45	porB1a.l15.c4.ctg.1	1538	14.8	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1232	1234	AAT	8;8;8	A;A;T	8;8;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	76	porB1a	984	331	90.45	porB1a.l15.c4.ctg.1	1538	14.8	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1235	1237	AAT	8;8;8	A;A;T	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	76	porB1a	984	331	90.45	porB1a.l15.c4.ctg.1	1538	14.8	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1247	1249	GTT	9;9;9	G;T;T	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	76	porB1a	984	331	90.45	porB1a.l15.c4.ctg.1	1538	14.8	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1259	1261	GCA	10;10;10	G;C;A	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	76	porB1a	984	331	90.45	porB1a.l15.c4.ctg.1	1538	14.8	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1282	1284	GTA	10;10;10	G;T;A	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	76	porB1a	984	331	90.45	porB1a.l15.c4.ctg.1	1538	14.8	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1294	1294	G	10	G	8	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	652	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1893	102.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	659	661	GGA	135;134;134	G;G;A	115;113;117	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	652	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1893	102.0	0	.	p	.	0	G50N	NONSYN	148	150	GGC	665	667	AAC	132;132;132	A;A;C	115;115;112	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	652	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1893	102.0	0	.	p	.	0	F135L	NONSYN	403	405	TTT	920	922	CTT	107;107;107	C;T;T,G	94;93;95,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	652	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1893	102.0	0	.	p	.	0	R143G	NONSYN	427	429	AGA	944	946	GGA	110;109;107	G;G;A	102;99;96	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	652	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1893	102.0	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1028	1030	GGT	110;110;110	G;G;T	102;98;100	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	652	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1893	102.0	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1082	1084	AGC	122;122;123	A;G;C	104;107;108	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	652	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1893	102.0	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1148	1148	T	132	T	108	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	652	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1893	102.0	1	SNP	p	G120K	0	.	.	358	360	GGT	875	877	GGT	111;112;112	G,T;G;T	94,1;97;91	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	652	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1893	102.0	1	SNP	p	A121N	0	.	.	361	363	GCC	878	880	GCC	112;112;111	G;C;C	94;95;97	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	652	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1893	102.0	1	SNP	p	A121D	0	.	.	361	363	GCC	878	880	GCC	112;112;111	G;C;C	94;95;97	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2232	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	5236	127.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2151	2153	AAT	153;152;151	A;A;T	123;124;124	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	352	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1315	80.1	1	SNP	p	V57M	1	.	.	169	171	ATG	675	677	ATG	133;134;135	A;T;G	107;110;108	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
